]>
IRCT20190707044123N1 IRCT 2019-07-15 Rasht University of Medical Sciences Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patients Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patients 2019-07-16 anticipated 64 Complete https://irct.ir/trial/40633 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: After convenience sampling, Participants will be assigned to three groups of 32 people using closed envelopes with blocked randomization method. Blocking will be used to create the number of samples assigned to each treatment group. In this study, people will be divided into 16 blocks of 4. Patients with the ability to enter this clinical trial are categorized as 1 to 1 in two groups of intervention and control. 3 Schizophrenia. Intervention 1: Intervention group: Individuals in intervention group will receive for 6 weeks a Famotidine ( 40 mg, daily). Also patients will receive their standard Psychiatric medication(Olanzapine at a dosage of 10 to 25 mg, daily). Intervention 2: Control group: Individuals in control group will receive their standard Psychiatric medication (Olanzapine at a dosage of 10 to 25 mg, daily). Yes - There is a plan to make this available What will be shared: Only part of the data, such as the key outcome information or the like, can share. When: The beginning of the access period since early 2020 To whom: It will be available to doctors and researchers working in academic and academic institutions. Conditions: Eligible persons can send their application by e-mail to access relevant information so that they can be sent to them if they identify the project implementer. Where to obtain: Email to head of project How to obtain: After the email is submitted to the head of project, the requesting person will receive the response within a few days. Comments:
public Mona Mousaei
15 khordad avenue, Shafa Hospital, Rasht, Iran
Rasht Iran (Islamic Republic of) 41939-55599 +98 13 3366 6268 monamusaie@yahoo.com Rasht University of Medical Sciences scientific Dr Ali Pourramzani
15 khordad avenue, Shafa Hospital, Rasht, Iran
Rasht Iran (Islamic Republic of) 41939-55599 +98 13 3366 6268 ali.pourramazani@gums.ac.ir Rasht University of Medical Sciences Iran (Islamic Republic of) The diagnosis of schizophrenia based on Diagnostic and Statistical Manual of Psychiatric Disorders (DSM5) Patients receiving second-generation drugs A year past diagnosis of schizophrenia Patients have a secondary school education 25 years 50 years Both Sensitivity to famotidine Drug abuse Serious medical illness (Nephrology disease) F20 Schizophrenia Treatment - Drugs Treatment - Other Intervention group: Individuals in intervention group will receive for 6 weeks a Famotidine ( 40 mg, daily). Also patients will receive their standard Psychiatric medication(Olanzapine at a dosage of 10 to 25 mg, daily). Control group: Individuals in control group will receive their standard Psychiatric medication (Olanzapine at a dosage of 10 to 25 mg, daily). Symptoms of schizophrenia. Timepoint: The effectiveness of the treatment will be evaluated in Baseline and Six weeks after the intervention. Method of measurement: The effectiveness of the treatment will be evaluated in Baseline and Six weeks after the intervention based on the score obtained from the Wechsler Memory Scale(WMS) and Positive and Negative Symptoms of Schizophrenia(PANSS). Rasht University of Medical Sciences Approved 2019-06-26 Ethics committee of Guilan University of Medical Sciences Deputy of Research and Technology University, The old building of the School of Health, in front of 17 shahrivar Hospital, Shahid Siadati St., Namjoo St. Rasht Guilan Iran (Islamic Republic of)